ERBB2 and breast carcinoma: Overall, the HER2/neu peptide vaccine for breast cancer remains a novel and feasible anti-cancer strategy with only a few clinical outcomes being discovered and the majority of the completed clinical trials are concerned about the disease recurrence instead of curing cancer.